RxDoctor Payments Data

Carl Stein, PA

Medical · San Francisco, CANPI 1053346957

Payments from drug & device makers

$14,969in general payments, 2019–2025

Across 84 payments — averaging $178.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$13K
  • Gilead$767
  • AbbVie$257
  • Vertex$222
  • Janssen Products, LP$180
  • Merck$172
  • plus $727 from 6 others

What the payments were for

  • Consulting fees$10,26069%
  • Speaking & faculty fees$7205%
  • Travel & lodging$7575%
  • Food & beverage$3,05220%
  • Education$1801%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,969 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$49,109
Medicare patients
146
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi46$275,596
BiktarvyBictegrav/Emtricit/Tenofov Ala44$201,980
OdefseyEmtricitab/Rilpiviri/Tenof Ala28$137,195
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf26$127,067
TivicayDolutegravir Sodium39$112,693
DovatoDolutegravir Sodium/Lamivudine27$106,143
IsentressRaltegravir Potassium36$74,598
GenvoyaElviteg/Cob/Emtri/Tenof Alafen16$72,624
JulucaDolutegravir/Rilpivirine13$53,147
DescovyEmtricitabine/Tenofov Alafenam24$51,784
Isentress HdRaltegravir Potassium27$50,942
Etravirine36$38,274
PrezcobixDarunavir/Cobicistat13$31,480
EdurantRilpivirine Hcl13$26,656
Darunavir25$21,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Juluca$12,644$547,580125 claims
GileadBiktarvy, Genvoya, Descovy, Vemlidy$767$345,23297 claims
Janssen Products, LPSymtuza$180$127,06726 claims
MerckIsentress, Isentress Hd$172$125,54063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →